📍We're at #BIO2026 in San Diego!
Peptomyc's CEO @jesmartingarcia and CSO @LauraSoucek are attending the event as part of the 🇪🇸 Spanish Pavilion with @ICEX_, meeting partners and industry leaders to discuss innovation in oncology and therapies targeting MYC in cancers.
#RAS showed the world that "undruggable" targets can be drugged.
We're honored to see a recent @Nature News & Views point to #MYC as a promising next frontier and to see @peptomyc mentioned among those moving the field forward.
The journey continues.
https://t.co/p5jbiq0Pdz
Encouraging to see positive Phase 3 results with #daraxonrasib in previously treated mPDAC, where every meaningful advance matters. Milestones like this reinforce the value of pursuing bold science against difficult targets.
#RASi#MYCi
https://t.co/SChLYVp6F6
Peptomyc closes €5 Million Equity Financing to advance OMO-103 toward the next stage of development.
Read the Press release here: https://t.co/p0kMbAmDmh
Frontiers in Cancer Research and Therapy 2026 conference" hosted by @karolinskainst "in Stockholm. Our Co-founder & CSO, @LauraSoucek, delivered today a compelling talk pushing the boundaries of what’s possible in targeting one of the most challenging drivers in cancer. #Cancer
Last Friday, @LauraSoucek, our CSO and co-founder, was invited as a speaker at the #PhDDay of the @IIBmCSICUAM, CIBERER / @IdiPAZScience in Madrid. She shared her insights, experiences, and perspective with the next generation of researchers.
Last Friday I was an invited speaker at the PhD Day of @IIBM_CSIC / CSIC-UAM / CIBERER / IdiPaz in Madrid.
I talked about the journey toward a clinically viable MYC inhibitor and my path as a researcher (@VHIO, @icreacommunity, @LSoucekLab) and entrepreneur (@peptomyc).
New review out in @FrontImmunol! 🎉
@VHIO@icreacommunity@LSoucekLab and @peptomyc explore how the oncogene MYC drives immune evasion and resistance to cancer immunotherapy—and why targeting MYC could help restore antitumor immunity.
👉 https://t.co/a3SeIDnDdA
🗞️Una revisió publicada a @FrontCellDevBio
amb participació de l'#investigadorICREA@LauraSoucek (@VHIO@peptomyc), analitza com la combinació d'inhibidors oncogènics MYC amb teràpies dirigides obre noves oportunitats terapèutiques.
https://t.co/ptPrZpOHs8
Back from San Francisco 🇺🇸 During #JPMHealthcare week, Peptomyc’s CEO @jesmartingarcia and CSO @LauraSoucek met with pharmaceutical partners to explore strategic collaborations.
Strong discussions, shared vision, and exciting next steps ahead.
📍 San Francisco
#Partnerships
Ayer @LauraSoucek , nuestra CSO, participó como Keynote Speaker en la 19ª Jornada Científica y 29ª Conferencia Anual del Hospital Vall d’Hebron ✨
Agradecemos al @vallhebron por crear un espacio de intercambio tan enriquecedor.
https://t.co/6hdla6IXvW
#MYC#KeynoteSpeaker
Nos complace compartir que la Dra. @LauraSoucek participó ayer, miércoles 3 de diciembre, como ponente en la XV edición del @CNIOStopCancer Lab Day, aportando su visión científica y emprendedora. Muchas gracias al equipo organizador! @msmelanoma
Groundbreaking research advances OMO-103 as a potential combination therapy for treatment-resistant breast cancer. Fabio Giuntini & @LauraSoucek
Read the full publication: https://t.co/9bXpBwqxZ4
Huge thanks to Fabio Giuntini, and to the entire teams at @VHIO and @peptomyc for making this possible. We also want to acknowledge the support of @CMMetastasico and the @ERC_Research for backing research that can make a real difference.